Loading...

Statistical considerations in biosimilar assessment using biosimilarity index

When an innovative biologic product goes off patent, biopharmaceutical or biotechnological companies may file an application for regulatory approval of biosimilar products. Unlike small molecule drug products, biosimilars are not exact copies of their brand-name counterpart, and they are usually ver...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhang, Aijing, Tzeng, Jung-Ying, Chow, Shein-Chung
Format: Artigo
Language:Inglês
Published: 2012
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3967514/
https://ncbi.nlm.nih.gov/pubmed/24683298
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4172/jbb.1000160
Tags: Add Tag
No Tags, Be the first to tag this record!